The phase 3 KATHERINE trial tested 14 cycles of trastuzumab versus trastuzumab emtansine (T-DM1), an antibody–drug conjugate adjuvant therapy in HER2-positive breast cancer patients with residual disease after neoadjuvant treatment. This evidence concerns the gene ERBB2 and breast cancer.